×
验证码:
换一张
忘记密码?
记住我
CORC
首页
科研机构
检索
知识图谱
申请加入
托管服务
登录
注册
在结果中检索
科研机构
西北高原生物研究所 [27]
中国医学科学院 北... [10]
复旦大学上海医学院 [7]
西安交通大学 [4]
中国农业科学院 [4]
中南大学 [4]
更多...
内容类型
期刊论文 [68]
会议论文 [6]
发表日期
2019 [4]
2018 [7]
2017 [9]
2016 [10]
2015 [12]
2014 [13]
更多...
学科主题
林业 [2]
×
知识图谱
CORC
开始提交
已提交作品
待认领作品
已认领作品
未提交全文
收藏管理
QQ客服
官方微博
反馈留言
浏览/检索结果:
共74条,第1-10条
帮助
已选(
0
)
清除
条数/页:
5
10
15
20
25
30
35
40
45
50
55
60
65
70
75
80
85
90
95
100
排序方式:
请选择
作者升序
作者降序
题名升序
题名降序
发表日期升序
发表日期降序
提交时间升序
提交时间降序
Nivolumab Versus Docetaxel in a Predominantly Chinese Patient Population With Previously Treated Advanced NSCLC: CheckMate 078 Randomized Phase III Clinical Trial
期刊论文
JOURNAL OF THORACIC ONCOLOGY, 2019, 卷号: 14, 期号: 5
作者:
Wu, Yi-Long
收藏
  |  
浏览/下载:29/0
  |  
提交时间:2019/12/05
Chinese population
Nivolumab
NSCLC
Phase III clinical study
Self-Assembly of Therapeutic Peptide into Stimuli-Responsive Clustered Nanohybrids for Cancer-Targeted Therapy
期刊论文
ADVANCED FUNCTIONAL MATERIALS, 2019, 卷号: 29
作者:
He, Wangxiao
;
Wang, Simeng
;
Yan, Jin
;
Qu, Yiping
;
Jin, Liang
收藏
  |  
浏览/下载:31/0
  |  
提交时间:2019/11/19
peptide-derived nanocluster
tumor microenvironment-responsiveness
cancer targeted therapy
immunotherapy
peptide-Au nanohybrids
Nivolumab Versus Docetaxel in a Predominantly Chinese Patient Population With Previously Treated Advanced Non-Small Cell Lung Cancer: CheckMate 078 Randomized Phase III Clinical Trial
期刊论文
Journal of Thoracic Oncology, 2019
作者:
Yi-Long Wu
;
Shun Lu
;
Ying Cheng
;
Caicun Zhou
;
Jie Wang
收藏
  |  
浏览/下载:15/0
  |  
提交时间:2019/02/25
Chinese
population
nivolumab
non-small
cell
lung
cancer
phase
III
clinical
study
Nivolumab Versus Docetaxel in a Predominantly Chinese Patient Population With Previously Treated Advanced NSCLC: CheckMate 078 Randomized Phase III Clinical Trial
期刊论文
2019, 卷号: 14, 期号: 5, 页码: 867-875
作者:
Wu, Yi-Long
;
Lu, Shun
;
Cheng, Ying
;
Zhou, Caicun
;
Wang, Jie
收藏
  |  
浏览/下载:14/0
  |  
提交时间:2020/01/03
Chinese population
Nivolumab
NSCLC
Phase III clinical study
Nivolumab versus docetaxel in a predominantly Chinese patient population with previously treated advanced non-small cell lung cancer (NSCLC): results of the phase 3 CheckMate 078 study
会议论文
作者:
Wu, Yi-Long
;
Lu, Shun
;
Cheng, Ying
;
Zhou, Caicun
;
Wang, Jie
收藏
  |  
浏览/下载:11/0
  |  
提交时间:2019/12/05
Chinese Lupus Treatment and Research group (CSTAR) registry: X. family history in relation to lupus clinical and immunological manifestations
期刊论文
Clinical and Experimental Rheumatology, 2018, 卷号: 36, 页码: 81-87
作者:
Leng, Xiaomei
;
Li, Mengtao
;
Li, Xiangpei
;
Zhang, Xiao
;
Liu, Shengyun
收藏
  |  
浏览/下载:106/0
  |  
提交时间:2019/11/19
CSTAR
Family history
Lupus
Phenotypes
Anlotinib as a third-line therapy in patients with refractory advanced non-small-cell lung cancer: a multicentre, randomised phase II trial (ALTER0302)
期刊论文
British Journal of Cancer, 2018, 卷号: 118, 期号: 5, 页码: 654-661
作者:
Han, Baohui*
;
Li, Kai
;
Zhao, Yizhuo
;
Li, Baolan
;
Cheng, Ying
收藏
  |  
浏览/下载:9/0
  |  
提交时间:2019/12/03
non-small-cell lung cancer
multitarget
tyrosine kinase inhibitor
anlotinib
third line
Copper in depressive disorder: a systematic review and meta-analysis of observational studies
期刊论文
Psychiatry Research, 2018
作者:
Mengmei Ni
;
Yiping You
;
Jinyao Chen
;
Lishi Zhang
收藏
  |  
浏览/下载:8/0
  |  
提交时间:2019/02/28
Blood
copper
Depression
Biomarker
Pooled
analysis
Anlotinib as a third-line therapy in patients with refractory advanced non-small-cell lung cancer: a multicentre, randomised phase II trial (ALTER0302)
期刊论文
2018, 卷号: 118, 期号: 5, 页码: 654-661
作者:
Han, Baohui
;
Li, Kai
;
Zhao, Yizhuo
;
Li, Baolan
;
Cheng, Ying
收藏
  |  
浏览/下载:9/0
  |  
提交时间:2020/01/03
non-small-cell lung cancer
multitarget
tyrosine kinase inhibitor
anlotinib
third line
Nivolumab versus docetaxel in a predominantly Chinese patient population with previously treated advanced non-small cell lung cancer (NSCLC): results of the phase 3 CheckMate 078 study
期刊论文
2018, 卷号: 78, 期号: 13
作者:
Wu, Yi-Long
;
Lu, Shun
;
Cheng, Ying
;
Zhou, Caicun
;
Wang, Jie
收藏
  |  
浏览/下载:3/0
  |  
提交时间:2020/01/03
©版权所有 ©2017 CSpace - Powered by
CSpace